Skip to content

Study · Not a test of the peptide alone · 2015

6 results

The Therapeutic Effects of Thymosin α1 Combined with Human Immunoglobulin (Ig) and Bundles on Severe Sepsis: a Retrospective Study.

Li Y, Li CS

Clinical laboratory1 Jan 2015Cited by 1 (Europe PMC)

PMID26427133 (opens in a new tab)DOI10.7754/clin.lab.2015.150110 (opens in a new tab)PepBankPUB-26427133
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In adults with severe sepsis in intensive care, bundles combined with immunoglobulin and thymosin alpha‑1 reduced days of artificial ventilation compared with bundles alone.

    In plain wordsIn people with severe sepsis, a regimen of immunoglobulin plus thymosin alpha‑1 was linked to fewer ventilator days than standard bundles alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDays of artificial ventilation
    Study

    n = 526

    Comparator
    Bundles alone
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    Compared with the B group, the number of days of artificial ventilation was decreased (p < 0.005) and ICU stay shortened (p < 0.001) in the A group.
    2 context sentences
    Summary · context
    A total of 526 subjects with severe sepsis in the ICU were divided into two groups: bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy (A group) and bundles (B group).
    Summary · context
    Bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy was administrated to 221 patients. 305 patients were treated with bundles.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In adults with severe sepsis, bundles combined with immunoglobulin and thymosin alpha‑1 shortened ICU stay compared with bundles alone.

    In plain wordsIn people with severe sepsis, a regimen of immunoglobulin plus thymosin alpha‑1 was linked to shorter ICU stays than standard bundles alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseICU stay
    Study

    n = 526

    Comparator
    Bundles alone
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    Compared with the B group, the number of days of artificial ventilation was decreased (p < 0.005) and ICU stay shortened (p < 0.001) in the A group.
    2 context sentences
    Summary · context
    A total of 526 subjects with severe sepsis in the ICU were divided into two groups: bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy (A group) and bundles (B group).
    Summary · context
    Bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy was administrated to 221 patients. 305 patients were treated with bundles.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    After 14 days, APACHE II scores were decreased in the group that received bundles with immunoglobulin and thymosin alpha‑1.

    In plain wordsIn people with severe sepsis, an illness severity score fell after 14 days with immunoglobulin plus thymosin alpha‑1 regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAPACHE II score at day 14
    Study

    n = 526

    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    After 14 days of treatment, APACHE II and SOFA scores were decreased (both p < 0.001).
    2 context sentences
    Summary · context
    A total of 526 subjects with severe sepsis in the ICU were divided into two groups: bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy (A group) and bundles (B group).
    Summary · context
    Bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy was administrated to 221 patients. 305 patients were treated with bundles.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    After 14 days, SOFA scores were decreased in the group that received bundles with immunoglobulin and thymosin alpha‑1.

    In plain wordsIn people with severe sepsis, an organ failure score fell after 14 days with immunoglobulin plus thymosin alpha‑1 regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSOFA score at day 14
    Study

    n = 526

    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    After 14 days of treatment, APACHE II and SOFA scores were decreased (both p < 0.001).
    2 context sentences
    Summary · context
    A total of 526 subjects with severe sepsis in the ICU were divided into two groups: bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy (A group) and bundles (B group).
    Summary · context
    Bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy was administrated to 221 patients. 305 patients were treated with bundles.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    Mortality was decreased by 13.89% in the group that received bundles with immunoglobulin and thymosin alpha‑1.

    In plain wordsIn people with severe sepsis, deaths were fewer with the immunoglobulin plus thymosin alpha‑1 regimen than with bundles alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMortality
    Study

    n = 526

    Comparator
    Bundles alone
    Outcome group
    Mortality · Whole body

    Measurements

    Mortality reduction
    13.89%
    bundles with immunoglobulin and thymosin alpha 1 versus bundles

    Source sentences

    Summary
    Mortality in the A group was decreased by 13.89% (p < 0.005).
    2 context sentences
    Summary · context
    A total of 526 subjects with severe sepsis in the ICU were divided into two groups: bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy (A group) and bundles (B group).
    Summary · context
    Bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy was administrated to 221 patients. 305 patients were treated with bundles.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    The survival period was longer in the group that received bundles with immunoglobulin and thymosin alpha‑1 than in the bundles group.

    In plain wordsIn people with severe sepsis, survival time was longer with the immunoglobulin plus thymosin alpha‑1 regimen than with bundles alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival period
    Study

    n = 526

    Comparator
    Bundles alone
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    The survival period in the A group was longer than that of the B group (p < 0.001).
    2 context sentences
    Summary · context
    A total of 526 subjects with severe sepsis in the ICU were divided into two groups: bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy (A group) and bundles (B group).
    Summary · context
    Bundles combined with human immunoglobulin (Ig) and thymosin α1 therapy was administrated to 221 patients. 305 patients were treated with bundles.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.